| Basics |
Nektar Therapeutics
Nektar Therapeutics Inc is a biopharmaceutical company engaged in the development of new molecules to treat diseases with unmet medical needs. The company is researching and developing drugs for treating cancer, auto-immune disease and chronic pain.
|
| IPO Date: |
May 3, 1994 |
| Sector: |
Healthcare |
| Industry: |
Pharma |
| Market Cap: |
$1.16B |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$0.39 | 2.59%
|
| Avg Daily Range (30 D): |
$2.06 | 3.48%
|
| Avg Daily Range (90 D): |
$1.62 | 3.37%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
1.45M |
| Avg Daily Volume (30 D): |
.62M |
| Avg Daily Volume (90 D): |
.79M |
| Trade Size |
| Avg Trade Size (Sh.): |
164 |
| Avg Trade Size (Sh.) (30 D): |
59 |
| Avg Trade Size (Sh.) (90 D): |
69 |
| Institutional Trades |
| Total Inst.Trades: |
9,158 |
| Avg Inst. Trade: |
$2.69M |
| Avg Inst. Trade (30 D): |
$2.66M |
| Avg Inst. Trade (90 D): |
$2.74M |
| Avg Inst. Trade Volume: |
.01M |
| Avg Inst. Trades (Per Day): |
2 |
| Market Closing Trades |
| Avg Closing Trade: |
$4.89M |
| Avg Closing Trade (30 D): |
$3.17M |
| Avg Closing Trade (90 D): |
$3.14M |
| Avg Closing Volume: |
17.01K |
|
|
| Financials |
| |
TTM |
Q3 2025 |
Q2 2025 |
|
Basic EPS
|
$3.63
|
$-1.87
|
$-2.95
|
|
Diluted EPS
|
$3.63
|
$-1.87
|
$-2.95
|
|
Revenue
|
$ 62.6M
|
$ 11.79M
|
$ 11.18M
|
|
Gross Profit
|
$
|
$
|
$
|
|
Net Income / Loss
|
$ -120.74M
|
$ -35.52M
|
$ -41.59M
|
|
Operating Income / Loss
|
$ -98.09M
|
$ -31.67M
|
$ -36.23M
|
|
Cost of Revenue
|
$ 7.98M
|
$ M
|
$ M
|
|
Net Cash Flow
|
$ 10.92M
|
$ -1.96M
|
$ 4.09M
|
|
PE Ratio
|
16.07
|
|
|
| Splits |
|
Jun 09, 2025:
1:15
|
|
Aug 23, 2000:
2:1
|
|
|
|
